Showing results (61-70 of 101) with videos related to
Sort By:
Pageof 11
JAMA Neurology|June 5, 2023
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab CessationChao Zhu, Tomas Kalincik, Dana Horakova, et al.Brain : a Journal of Neurology|July 13, 2016
Defining secondary progressive multiple sclerosisJohannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, et al.Journal of Neurology, Neurosurgery, and Psychiatry|January 15, 2019
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosisTomas Kalincik, Eva Kubala Havrdova, Dana Horakova, et al.Annals of Neurology|October 7, 2014
Seasonal variation of relapse rate in multiple sclerosis is latitude dependentTim Spelman, Orla Gray, Maria Trojano, et al.Multiple Sclerosis and Related Disorders|January 10, 2019
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort studyAi-Lan Nguyen, Eva Kubala Havrdova, Dana Horakova, et al.Journal of Neurology, Neurosurgery, and Psychiatry|April 3, 2024
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort studyCathérine Dekeyser, Matthias Hautekeete, Melissa Cambron, et al.Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase RegistryJuan Ignacio Rojas, Liliana Patrucco, Maria Trojano, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|June 16, 2020
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosisMinh Le, Charles Malpas, Sifat Sharmin, et al.Journal of Neurology, Neurosurgery, and Psychiatry|November 5, 2016
Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosisChunrong Tao, Steve Simpson, Ingrid van der Mei, et al.The Lancet. Neurology|February 18, 2017
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort studyTomas Kalincik, J William L Brown, Neil Robertson, et al.Pageof 11